These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 12549983

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 3. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 6. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.
    Int J Cardiol; 2005 Oct 10; 104(3):338-45. PubMed ID: 16186066
    [Abstract] [Full Text] [Related]

  • 7. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E.
    Arterioscler Thromb Vasc Biol; 2009 Mar 10; 29(3):424-30. PubMed ID: 19122170
    [Abstract] [Full Text] [Related]

  • 8. Short-term effects of atorvastatin on C-reactive protein.
    Riesen WF, Engler H, Risch M, Korte W, Noseda G.
    Eur Heart J; 2002 May 10; 23(10):794-9. PubMed ID: 12009719
    [Abstract] [Full Text] [Related]

  • 9. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A, Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group.
    Am Heart J; 2004 Apr 10; 147(4):705-13. PubMed ID: 15077101
    [Abstract] [Full Text] [Related]

  • 10. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G, Di Garbo V, Abruzzese G, Campisi D, De Simone R, Raneli G, Licata G.
    Int Angiol; 2006 Mar 10; 25(1):26-34. PubMed ID: 16520721
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW, STELLAR Study Group.
    Curr Med Res Opin; 2003 Mar 10; 19(8):689-98. PubMed ID: 14687438
    [Abstract] [Full Text] [Related]

  • 12. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E, PROVE IT-TIMI 22 Investigators.
    J Am Coll Cardiol; 2005 Oct 18; 46(8):1417-24. PubMed ID: 16226164
    [Abstract] [Full Text] [Related]

  • 13. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators.
    N Engl J Med; 2005 Jan 06; 352(1):20-8. PubMed ID: 15635109
    [Abstract] [Full Text] [Related]

  • 14. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
    van der Harst P, Asselbergs FW, Hillege HL, Bakker SJ, Voors AA, van Veldhuisen DJ, van Gilst WH, PREVEND-IT Investigators.
    Am J Cardiol; 2007 Nov 15; 100(10):1548-51. PubMed ID: 17996517
    [Abstract] [Full Text] [Related]

  • 15. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE, Davidson M, Jones MR, Abby SL.
    Am J Cardiol; 2006 Apr 15; 97(8):1198-205. PubMed ID: 16616026
    [Abstract] [Full Text] [Related]

  • 16. Achieving lipid goals in real life: the Dutch DISCOVERY study.
    Bots AF, Kastelein JJ, Discovery Netherlands Investigators.
    Int J Clin Pract; 2005 Dec 15; 59(12):1387-94. PubMed ID: 16351669
    [Abstract] [Full Text] [Related]

  • 17. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
    Macin SM, Perna ER, Farías EF, Franciosi V, Cialzeta JR, Brizuela M, Medina F, Tajer C, Doval H, Badaracco R.
    Am Heart J; 2005 Mar 15; 149(3):451-7. PubMed ID: 15864233
    [Abstract] [Full Text] [Related]

  • 18. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D.
    Am J Cardiol; 2007 Jun 15; 99(12):1706-1713. PubMed ID: 17560879
    [Abstract] [Full Text] [Related]

  • 19. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
    Joukhadar C, Klein N, Prinz M, Schrolnberger C, Vukovich T, Wolzt M, Schmetterer L, Dorner GT.
    Thromb Haemost; 2001 Jan 15; 85(1):47-51. PubMed ID: 11204586
    [Abstract] [Full Text] [Related]

  • 20. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE.
    Am J Cardiol; 2005 Sep 05; 96(5A):61F-68F. PubMed ID: 16126025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.